Pfizer has announced a significant breakthrough in the treatment of severe alopecia areata in the UAE, catering to patients as young as 12 years old. This new once-daily oral capsule provides optimism for those facing the challenges posed by this autoimmune condition.
Alopecia areata is an autoimmune disorder in which the body's immune system erroneously attacks hair follicles, leading to patchy hair loss. Dr. Fatima Albreiki, the Scientific Committee Chairperson at Emirates Dermatology Society, emphasized the importance of advancing therapies that not only target the physical symptoms but also address the emotional impact of hair loss.
She expressed her belief that the introduction of this treatment in the UAE represents a promising development in the available treatment options for patients, potentially bringing about transformative changes in the lives of those affected. Serhat Yalcinkaya, Pfizer's Gulf Cluster Lead, highlighted the significance of this new treatment advancement for individuals as young as 12 years old.
